Compare GHRS & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GHRS | STEW |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 1996 |
| Metric | GHRS | STEW |
|---|---|---|
| Price | $18.52 | $18.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $42.89 | N/A |
| AVG Volume (30 Days) | ★ 323.8K | 83.5K |
| Earning Date | 11-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.04 | $16.55 |
| 52 Week High | $31.44 | $19.05 |
| Indicator | GHRS | STEW |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 61.44 |
| Support Level | $17.54 | $18.22 |
| Resistance Level | $22.51 | $19.05 |
| Average True Range (ATR) | 1.27 | 0.23 |
| MACD | 0.19 | 0.07 |
| Stochastic Oscillator | 21.68 | 49.23 |
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.